ArriVent BioPharma Inkomsten in het verleden
Verleden criteriumcontroles 0/6
ArriVent BioPharma's earnings have been declining at an average annual rate of -33.8%, while the Biotechs industry saw earnings growing at 19% annually.
Belangrijke informatie
-33.8%
Groei van de winst
87.8%
Groei van de winst per aandeel
| Biotechs Groei van de industrie | 17.0% |
| Inkomstengroei | n/a |
| Rendement op eigen vermogen | -25.2% |
| Nettomarge | n/a |
| Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Geen updates
Opbrengsten en kosten
Hoe ArriVent BioPharma geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -75 | 13 | 73 |
| 31 Mar 24 | 0 | -75 | 11 | 72 |
| 31 Dec 23 | 0 | -69 | 10 | 65 |
| 30 Sep 23 | 0 | -59 | 8 | 54 |
| 30 Jun 23 | 0 | -56 | 8 | 49 |
| 31 Mar 23 | 0 | -42 | 7 | 35 |
| 31 Dec 22 | 0 | -37 | 6 | 30 |
Kwaliteitswinsten: AVBP is currently unprofitable.
Groeiende winstmarge: AVBP is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: Insufficient data to determine if AVBP's year-on-year earnings growth rate was positive over the past 5 years.
Versnelling van de groei: Unable to compare AVBP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: AVBP is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Rendement op eigen vermogen
Hoge ROE: AVBP has a negative Return on Equity (-25.24%), as it is currently unprofitable.